Levels of lupus autoantibodies in pregnant SLE patients: Correlations with disease activity and pregnancy outcome

Yaron Tomer, O. A C Viegas, M. Swissa, S. C L Koh, Y. Shoenfeld

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

To follow the levels of lupus autoantibodies throughout pregnancy in a large cohort of pregnant SLE patients, and to examine whether they correlate with disease activity and pregnancy outcome. Methods: 54 pregnancies in 46 SLE patients, and 70 control pregnant women were followed in the study. All patients were receiving steroid treatment. Titers of antibodies to ssDNA. dsDNA, histones, cardiolipin (CL) and phosphatidylserine (PS) were determined at the first, second, and third trimester and post-partum by ELISA. Results: Overall the average levels of autantibodies in all the patients were within the normal range, except for the average levels of anti-dsDNA antibodies which were elevated during the second trimester. Eight women (14.5%) had active disease during pregnancy, and there was u significant correlation between the levels of anti-dsDNA and the risk of disease activity (p = 0.0225). There were 7 fetal losses. There was a tendency for correlation between elevated anti-dsDNA levels, and anti-CL levels and the risk of fetal loss; however, this did not reach statistical significance (p = 0.0685, and 0.0881, respectively). There was a significant correlation between the levels of anti-dsDNA antibodies and the risk of preterm delivery (p = 0,0331). Conclusions: Pregnancy in SLE patients is associated with significant complications to both the mother and the fetus. Anti-dsDNA levels seem to correlate with the risk of disease exacerbation, and prematurity. Elevated levels of anti-dsDNA and anti-CL may suggest an increase risk of fetal loss.

Original languageEnglish (US)
Pages (from-to)275-280
Number of pages6
JournalClinical and Experimental Rheumatology
Volume14
Issue number3
StatePublished - May 1996
Externally publishedYes

Fingerprint

Pregnancy Outcome
Autoantibodies
Cardiolipins
Pregnancy
Second Pregnancy Trimester
Anti-Idiotypic Antibodies
Phosphatidylserines
Third Pregnancy Trimester
First Pregnancy Trimester
Histones
Disease Progression
Pregnant Women
Reference Values
Fetus
Enzyme-Linked Immunosorbent Assay
Steroids
Mothers
Antibodies
Therapeutics

Keywords

  • anti-DNA
  • autoantibodies
  • pregnancy
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Levels of lupus autoantibodies in pregnant SLE patients : Correlations with disease activity and pregnancy outcome. / Tomer, Yaron; Viegas, O. A C; Swissa, M.; Koh, S. C L; Shoenfeld, Y.

In: Clinical and Experimental Rheumatology, Vol. 14, No. 3, 05.1996, p. 275-280.

Research output: Contribution to journalArticle

@article{f82a3046645743459d2b49af7dbd956d,
title = "Levels of lupus autoantibodies in pregnant SLE patients: Correlations with disease activity and pregnancy outcome",
abstract = "To follow the levels of lupus autoantibodies throughout pregnancy in a large cohort of pregnant SLE patients, and to examine whether they correlate with disease activity and pregnancy outcome. Methods: 54 pregnancies in 46 SLE patients, and 70 control pregnant women were followed in the study. All patients were receiving steroid treatment. Titers of antibodies to ssDNA. dsDNA, histones, cardiolipin (CL) and phosphatidylserine (PS) were determined at the first, second, and third trimester and post-partum by ELISA. Results: Overall the average levels of autantibodies in all the patients were within the normal range, except for the average levels of anti-dsDNA antibodies which were elevated during the second trimester. Eight women (14.5{\%}) had active disease during pregnancy, and there was u significant correlation between the levels of anti-dsDNA and the risk of disease activity (p = 0.0225). There were 7 fetal losses. There was a tendency for correlation between elevated anti-dsDNA levels, and anti-CL levels and the risk of fetal loss; however, this did not reach statistical significance (p = 0.0685, and 0.0881, respectively). There was a significant correlation between the levels of anti-dsDNA antibodies and the risk of preterm delivery (p = 0,0331). Conclusions: Pregnancy in SLE patients is associated with significant complications to both the mother and the fetus. Anti-dsDNA levels seem to correlate with the risk of disease exacerbation, and prematurity. Elevated levels of anti-dsDNA and anti-CL may suggest an increase risk of fetal loss.",
keywords = "anti-DNA, autoantibodies, pregnancy, systemic lupus erythematosus",
author = "Yaron Tomer and Viegas, {O. A C} and M. Swissa and Koh, {S. C L} and Y. Shoenfeld",
year = "1996",
month = "5",
language = "English (US)",
volume = "14",
pages = "275--280",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "3",

}

TY - JOUR

T1 - Levels of lupus autoantibodies in pregnant SLE patients

T2 - Correlations with disease activity and pregnancy outcome

AU - Tomer, Yaron

AU - Viegas, O. A C

AU - Swissa, M.

AU - Koh, S. C L

AU - Shoenfeld, Y.

PY - 1996/5

Y1 - 1996/5

N2 - To follow the levels of lupus autoantibodies throughout pregnancy in a large cohort of pregnant SLE patients, and to examine whether they correlate with disease activity and pregnancy outcome. Methods: 54 pregnancies in 46 SLE patients, and 70 control pregnant women were followed in the study. All patients were receiving steroid treatment. Titers of antibodies to ssDNA. dsDNA, histones, cardiolipin (CL) and phosphatidylserine (PS) were determined at the first, second, and third trimester and post-partum by ELISA. Results: Overall the average levels of autantibodies in all the patients were within the normal range, except for the average levels of anti-dsDNA antibodies which were elevated during the second trimester. Eight women (14.5%) had active disease during pregnancy, and there was u significant correlation between the levels of anti-dsDNA and the risk of disease activity (p = 0.0225). There were 7 fetal losses. There was a tendency for correlation between elevated anti-dsDNA levels, and anti-CL levels and the risk of fetal loss; however, this did not reach statistical significance (p = 0.0685, and 0.0881, respectively). There was a significant correlation between the levels of anti-dsDNA antibodies and the risk of preterm delivery (p = 0,0331). Conclusions: Pregnancy in SLE patients is associated with significant complications to both the mother and the fetus. Anti-dsDNA levels seem to correlate with the risk of disease exacerbation, and prematurity. Elevated levels of anti-dsDNA and anti-CL may suggest an increase risk of fetal loss.

AB - To follow the levels of lupus autoantibodies throughout pregnancy in a large cohort of pregnant SLE patients, and to examine whether they correlate with disease activity and pregnancy outcome. Methods: 54 pregnancies in 46 SLE patients, and 70 control pregnant women were followed in the study. All patients were receiving steroid treatment. Titers of antibodies to ssDNA. dsDNA, histones, cardiolipin (CL) and phosphatidylserine (PS) were determined at the first, second, and third trimester and post-partum by ELISA. Results: Overall the average levels of autantibodies in all the patients were within the normal range, except for the average levels of anti-dsDNA antibodies which were elevated during the second trimester. Eight women (14.5%) had active disease during pregnancy, and there was u significant correlation between the levels of anti-dsDNA and the risk of disease activity (p = 0.0225). There were 7 fetal losses. There was a tendency for correlation between elevated anti-dsDNA levels, and anti-CL levels and the risk of fetal loss; however, this did not reach statistical significance (p = 0.0685, and 0.0881, respectively). There was a significant correlation between the levels of anti-dsDNA antibodies and the risk of preterm delivery (p = 0,0331). Conclusions: Pregnancy in SLE patients is associated with significant complications to both the mother and the fetus. Anti-dsDNA levels seem to correlate with the risk of disease exacerbation, and prematurity. Elevated levels of anti-dsDNA and anti-CL may suggest an increase risk of fetal loss.

KW - anti-DNA

KW - autoantibodies

KW - pregnancy

KW - systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0029784089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029784089&partnerID=8YFLogxK

M3 - Article

C2 - 8809441

AN - SCOPUS:0029784089

VL - 14

SP - 275

EP - 280

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 3

ER -